featured
Isatuximab Plus Carfilzomib/Dexamethasone for Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
Lancet Haematol 2024 Jul 24;[EPub Ahead of Print], K Yong, T Martin, MA Dimopoulos, J Mikhael, M Capra, T Facon, R Hajek, I Špička, R Baker, K Kim, G Martinez, CK Min, L Pour, X Leleu, A Oriol, Y Koh, K Suzuki, F Casca, S Macé, ML Risse, P MoreauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.